Skip to main content

Table 3 Multivariate Cox proportional hazards for re-hospitalization within 12 months

From: Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder

Covariate

Adjusted HR

95% CI

P-value

Rituximab exposure

0.71

0.38, 1.34

0.29

Male gender

0.68

0.35, 1.32

1.32

Caucasian

0.90

0.50, 1.61

0.72

Region (reference: Midwest)

 Northeast

0.74

0.28, 1.91

0.53

 South

0.70

0.33, 1.47

0.35

 West

1.09

0.40, 2.95

0.87

Length of Initial Stay (days)

0.98

0.94, 1.03

0.41

ICU status

1.41

0.61, 3.25

0.43

Receipt of PT

4.81

1.14, 20.29

0.03

Receipt of PLEX

1.01

0.49, 2.08

0.98

Glucocorticoid (reference: oral only)

 Intravenous only

0.88

0.28, 2.72

0.82

 Oral + intravenous

1.72

0.57, 5.18

0.33

  1. Physical therapy (PT) exposure defined as at least one procedure code for PT during initial hospitalization. Oral glucocorticoids defined as at least one billing code for dexamethasone, hydrocortisone, prednisone or prednisolone
  2. CI confidence interval, ICU intensive care unit, PLEX plasma exchange